MannKind Corporation successfully acquired scPharmaceuticals Inc. for $5.35 per share, expanding its cardiometabolic care portfolio and expected to drive double-digit revenue growth through FUROSCIX®, an innovative therapy for heart failure and kidney disease.

Law firm investigating potential securities law violations and fiduciary duty breaches for ZimVie, Aris Water Solutions, and scPharmaceuticals regarding their proposed sales and merger transactions.

MannKind Corporation announced it will acquire scPharmaceuticals for $303 million, expanding its presence in cardiometabolic and lung diseases. The deal includes an upfront cash payment of $5.35 per share and potential additional milestone payments, representing a 36% premium to scPharmaceuticals' recent trading price.

scPharmaceuticals Inc. announced a proposed underwritten public offering of shares of its common stock or pre-funded warrants to purchase shares. The offering is subject to market and other conditions.

BURLINGTON, Mass., May 29, 2024 (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (Nasdaq: SCPH), a pharmaceutical company focused on developing and commercializing products that have the potential to optimize the delivery of infused therapies, advance patient care, and reduce healthcare costs, today announced that John Tucker, President & Chief Execu...